KRAS and NRAS mutations are predictors of primary resistance to the EGFR-antibodies (EGFR-Abs) cetuximab and panitumumab in metastatic colorectal cancer (mCRC) [1,2,3,4,5]. The gene discussed is EGFR; the disease is metastatic colorectal cancer.